News

AstraZeneca’s CARES phase III clinical programme of anselamimab in light chain amyloidosis fails to meet primary endpoint: Cambridge, UK Thursday, July 17, 2025, 09:00 Hrs [IST] ...
Dr. George Tidmarsh, a Stanford pediatrics adjunct professor and former pharmaceutical executive, is FDA Commissioner Marty ...
Central to the deal are more than 250 Venezuelan migrants freed by El Salvador, which in March agreed to a $6 million payment from the Trump administration to house them in its notorious prison.
SIGNIFICANT EVENTS DURING 1 APRIL - 30 JUNE 2025In April, Iconovo announced an organizational change expected to reduce annual costs by approximately 14-16 MSEK starting in the third quarter of 2025.
AstraZeneca has announced a new clinical study titled ‘Exacerbations and Their Outcomes in Egyptian Patients (EXACOS EG Population),’ which aims to explore the burden of severe exacerbations ...
European stocks posted modest gains as positive earnings news diverted some of the market’s focus away from concerns about ...
Background Heart auscultation is a widely used and cost-effective clinical tool for detecting valvular heart disease (VHD), ...
AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar ...
US equity futures gained as a deluge of data is seen reinforcing the picture of a buoyant economy, diverting attention from ...
Shares of Summit Therapeutics jumped 9% Thursday on a report that it was discussing a lucrative partnership deal with AstraZeneca.
DelveInsight's THR-β Agonist Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...